John Reed's Insider Trades & SAST Disclosures
John Reed's most recent trade in Weatherford International plc - Ordinary Shares - New was a trade of 8,540 2025 Performance Share Units done . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John Reed.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 8,540 | 8,540 | - | - | 2025 Performance Share Units | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 5,693 | 5,693 | - | - | 2025 Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 15,927 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 2,698 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 15 Feb 2025 | 385 | 15,542 (0%) | 0% | 156.2 | 60,118 | Common Stock |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 10,279 | 0 | - | - | 2022 Annual Performance Share Units | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 10,279 | 24,444 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.36 per share. | 06 Feb 2025 | 4,045 | 20,399 (0%) | 0% | 65.4 | 264,381 | Ordinary Shares |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 2,824 | 13,933 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 2,824 | 0 | - | - | Restricted Share Units | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.99 per share. | 18 Jan 2025 | 1,986 | 14,165 (0%) | 0% | 74.0 | 146,944 | Ordinary Shares |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 1,491 | 1,491 | - | - | Restricted Share Units | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 1,491 | 15,424 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 727 | 1,452 | - | - | Restricted Share Units | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 727 | 16,151 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 72.66 per share. | 06 Jan 2025 | 4,762 | 11,109 (0%) | 0% | 72.7 | 346,007 | Ordinary Shares |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 26,377 | 0 | - | - | 2021 Program Performance Share Units | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 26,377 | 26,377 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.29 per share. | 02 Jan 2025 | 10,506 | 15,871 (0%) | 0% | 72.3 | 759,479 | Ordinary Shares |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 93.96 per share. | 05 Sep 2024 | 6,805 | 0 (0%) | 0% | 94.0 | 639,390 | Ordinary Shares |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 50,510 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 25,561 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 53,510 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 22,561 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 11,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 14,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 65,163 | 65,163 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | C. John Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,048 | 4,048 | - | - | Restricted Share Units | |
| Weatherford International ... | Reed David John | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 97.50 per share. | 15 Feb 2024 | 2,700 | 6,805 (0%) | 0% | 97.5 | 263,250 | Ordinary Shares |
| Weatherford International ... | David John Reed | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 3,268 | 3,268 | - | - | 2024 Annual Performance Share Units | |
| Weatherford International ... | John Reed David | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 2,824 | 2,824 | - | - | Restricted Share Units | |
| Weatherford International ... | David Reed John | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 2,824 | 9,629 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford International ... | Reed David John | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 2,724 | 2,724 | - | - | Restricted Share Units | |
| Weatherford International ... | David Reed John | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 2,179 | 2,179 | - | - | Restricted Share Units | |
| Weatherford International ... | Reed John David | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.50 per share. | 18 Jan 2024 | 1,615 | 9,505 (0%) | 0% | 94.5 | 152,618 | Ordinary Shares |
| Weatherford International ... | John David Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 1,491 | 2,982 | - | - | Restricted Share Units | |
| Weatherford International ... | John David Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 1,491 | 11,120 (0%) | 0% | 0 | Ordinary Shares | |
| Arhaus Inc - Ordinary Shar... | Reed John | Director, CEO and Chairman, Ten Percent Owner | 31 Dec 2023 | 769 | 10,769 | - | 9.1 | 7,002 | Class A Common Stock | |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | 31 Dec 2023 | 70 | 200 | - | 9.1 | 640 | Class A Common Stock | |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | 31 Dec 2023 | 30 | 130 | - | 9.1 | 274 | Class A Common Stock | |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 6.19 per share. | 13 May 2022 | 40,000 | 41,000 | - | 6.2 | 247,600 | Class A Common Stock |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jan 2022 | 7,035,433 | 0 | - | - | Class B Common Stock | |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 10 Dec 2021 | 10,000 | 10,000 | - | 10.5 | 105,000 | Class A Common Stock |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 10 Dec 2021 | 1,000 | 1,000 | - | 10.5 | 10,500 | Class A Common Stock |
| Arhaus Inc - Ordinary Shar... | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 10 Dec 2021 | 100 | 100 | - | 10.5 | 1,050 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges